Antidepressant pharmacogenetics

Current Opinion in Psychiatry

Volumn 27, Issue 1, 2014, Pages 43-51

  Singh, Ajeet B ^a   Bousman, Chad A ^b,c,d   Ng, Chee ^b   Berk, Michael ^a,b,c,e  

^a DEAKIN UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^e THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

Author keywords

antidepressants; biomarkers; major depression; pharmacogenetics; pharmacogenomics

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CATECHOL METHYLTRANSFERASE; CITALOPRAM; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DOPAMINE TRANSPORTER; ESCITALOPRAM; FK 506 BINDING PROTEIN; FLUOXETINE; GUANINE NUCLEOTIDE BINDING PROTEIN BETA POLYPEPTIDE 3; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; HEAT SHOCK PROTEIN 90; MIRTAZAPINE; MULTIDRUG RESISTANCE PROTEIN 1; NORADRENALIN TRANSPORTER; PAROXETINE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRYPTOPHAN HYDROXYLASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

BLURRED VISION; CONFOUNDING VARIABLE; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EFFECT SIZE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE ENVIRONMENT INTERACTION; HEARING DISORDER; HUMAN; MAJOR DEPRESSION; METHODOLOGY; PHARMACOGENETICS; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; SEXUAL DYSFUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VISUAL DISORDER;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; GENOME-WIDE ASSOCIATION STUDY; HUMANS; META-ANALYSIS AS TOPIC;

EID: 84889888298     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0000000000000023     Document Type: Review

References (86)

1. Murray CJ, Lopez AD. Evidence-based health policy: Lessons from the Global Burden of Disease Study. Science 1996; 274:740-743
2. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289:3095-3105
3. Wittchen H-U, Jacobi F. Size and burden of mental disorders in Europe: A critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005; 15:357-376
4. Kessler RC, Angermeyer M, Anthony JC, et al. Lifetime prevalence and ageof- onset distributions of mental disorders in the World Health Organization's World Mental Health Survey Initiative. World Psychiatry 2007; 6: 168-176
5. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54:405-418
6. Sartorius N. The economic and social burden of depression. J Clin Psychiatry 2001; 62 (Suppl 1):8-11
7. Simon GE. Social and economic burden of mood disorders. Biol Psychiatry 2003; 54:208-215
8. Thomas CM, Morris S. Cost of depression among adults in England in 2000. Br J Psychiatry 2003; 183:514-519
9. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: A patient-level meta-analysis. JAMA 2010; 303:47-53
10. Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: Analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009; 339:b2880
11. Amsterdam JD, Hornig-Rohan M. Treatment algorithms in treatment-resistant depression. Psychiatr Clin North Am 1996; 19:371-386
12. Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry 2001; 62 (Suppl 1):26-31
13. Thase ME. Effectiveness of antidepressants: Comparative remission rates. J Clin Psychiatry 2003; 64 (Suppl 2):3-7
14. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: A meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005; 66:974-981
15. Moncrieff J, Kirsch I. Efficacy of antidepressants in adults. BMJ 2005; 331: 155-157
16. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR-D report. Am J Psychiatry 2006; 163:1905-1917
17. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR-D: Implications for clinical practice. Am J Psychiatry 2006; 163:28-40
18. Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry 1999; 60 (Suppl 2):7-11
19. Zajecka J. Treating depression to remission. J Clin Psychiatry 2003; 64 (Suppl. 15):7s-12s.
20. Thase ME, Nierenberg AA, Vrijland P, et al. Remission with mirtazapine and selective serotonin reuptake inhibitors: A meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol 2010; 25:189-198
21. Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999; 286:487-491
22. Serrett A, Olgiati P. Pharmacogenetics of major depression: From research to clinical practice. Mind Body 2006; 3:19-31
23. O'Reilly RL, Bogue L, Singh SM. Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biol Psychiatry 1994; 36:467-471
24. Franchini L, Serretti A, Gasperini M, Smeraldi E. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res 1998; 32:255-259
25. Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997; 7:59-64
26. Varner RV, Ruiz P, Small DR. Black and white patients response to antidepressant treatment for major depression. Psychiatr Q 1998; 69:117- 125
27. Wagner GJ, Maguen S, Rabkin JG. Ethnic differences in response to fluoxetine in a controlled trial with depressed HIV-positive patients. Psychiatr Serv 1998; 49:239-240
28. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409:860-921
29. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291:1304-1351
30. Topol EJ, Murray SS, Frazer Ka. The genomics gold rush. JAMA 2007; 298:218-221
31. Bousman C, Chana G, Tatro ET, et al. Advances in genetic research, vol. 3. Urbano K, editor. Hauppauge, NY: Nova Science Publishers; 2009. p. 355
32. Bush WS, Moore JH. Genome-wide association studies. PLoS Comput Biol 2012; 8:e1002822
33. Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 2012; 22:239-258
34. Risch N, Herrell R, Lehner T, et al. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: A meta-analysis. JAMA 2009; 301:2462-2471
35. Yoshida K, Ito K, Sato K, et al. Influence of the serotonin transporter genelinked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26:383-386
36. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science 2003; 301:386- 389
37. Hu X, Zhu G, Lipsky RGD, Goldman D. HTTLPR allele expression is codominant, correlating with gene effects on fMRI and SPECT imaging intermediate phenotypes, and behavior. Biol Psychiatry 2004; 55 (Suppl 1):191S.
38. Niitsu T, Fabbri C, Bentini F, Serretti A. Pharmacogenetics in major depression: A comprehensive meta-analysis. Progr Neuropsychopharmacol Biol Psychiatry 2013; 45:183-194
39. Bah J, Lindstrom M, Westberg L, et al. Serotonin transporter gene polymorphisms: Effect on serotonin transporter availability in the brain of suicide attempters. Psychiatry Res 2008; 162:221-229
40. Nanni V, Uher R, Danese A, et al. Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: A meta-analysis. Am J Psychiatry 2008; 169:141-151
41. Antypa N, Drago A, Serretti A. Genome wide interaction and enrichment analysis on antidepressant response. Psychol Med 2013; July 1:1-13, available on CJO2013. doi:10.1017/S0033291713001554
42. Fava C, von Wowern F, Berglund G, et al. 24-h ambulatory blood pressure is linked to chromosome 18q21-22 and genetic variation of NEDD4L associates with cross-sectional and longitudinal blood pressure in Swedes. Kidney Int 2006; 70:562-569
43. Hunter AM, Leuchter AF, Power RA, et al. A genome-wide association study of a sustained pattern of antidepressant response. J Psychiatr Res 2013; 47:1157-1165
44. Adkins DE, Clark SL, Aberg K, et al. Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR-D. Transl Psychiatry 2012; 2:e129
45. Rada JA, Cornuet PK, Hassell Jr. Regulation of corneal collagen fibrillogenesis in vitro by corneal proteoglycan (lumican and decorin) core proteins. Exp Eye Res 1993; 56:635-648
46. Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: Patient report versus physician estimate. J Clin Psychiatry 2004; 65:959-965
47. Kurose K, Hiratsuka K, Ishiwata K, et al. Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression. Psychiatry Res 2012; 198:424-429
48. Hellquist A, Zucchelli M, Lindgren CM, et al. Identification of MAMDC1 as a candidate susceptibility gene for systemic lupus erythematosus (SLE). PLoS One 2009; 4:e8037
49. Joset P, Wacker A, Babey R, et al. Rostral growth of commissural axons requires the cell adhesion molecule MDGA2. Neural Dev 2011; 6:22
50. Myung W, Lim S-W, Kim S, et al. Serotonin transporter genotype and function in relation to antidepressant response in Koreans. Psychopharmacology 2013; 225:283-290
51. Won E-S, Chang H-S, Lee H-Y, et al. Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder. Neuropsychobiology 2012; 66:221-229
52. Singh AB, Bousman CA, Ng CH, et al. Psychomotor depressive symptoms may differentially respond to venlafaxine. Int Clin Psychopharmacol 2013; 28:121-126
53. Tiwari AK, Zai CC, Sajeev G, et al. Analysis of 34 candidate genes in bupropion and placebo remission. Int J Neuropsychopharmacol 2013; 16:771-781
54. Cutler JA, Rush AJ, McMahon FJ, Laje G. Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder. J Psychopharmacol 2012; 26:360- 367
55. Hopkins SC, Reasner DS, Koblan KS. Catechol-O-methyltransferase genotype as modifier of superior responses to venlafaxine treatment in major depressive disorder. Psychiatry Res 2013; 208:285-287
56. Arias B, Fabbri C, Gressier F, et al. TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: Possible effect in melancholic and psychotic depression. Neuropsychobiology 2013; 67:41-47
57. Hennings JM, Kohli MA, Czamara D, et al. Possible associations of NTRK2 polymorphisms with antidepressant treatment outcome: Findings from an extended tag SNP approach. PLoS One 2013; 8:e64947
58. Illi A, Viikki M, Poutanen O, et al. No support for a role for BDNF gene polymorphisms rs11030101 and rs61888800 in major depressive disorder or antidepressant response in patients of Finnish origin. Psychiatr Genet 2013; 23:33-35
59. Murphy GM, Sarginson JE, Ryan HS, et al. BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression. Pharmacogenet Genomics 2013; 23:301-313
60. Sasayama D, Hiraishi A, Tatsumi M, et al. Possible association of CUX1 gene polymorphisms with antidepressant response in major depressive disorder. Pharmacogenomics J 2012; 13:354-358
61. Chiesa A, Crisafulli C, Porcelli S, et al. Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder. Eur Arch Psychiatry Clin Neurosci 2012; 262:305-311
62. Fabbri C, Drago A, Serretti A. Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR(-)D. Eur Neuropsychopharmacol 2013; 23:612-621
63. Pu M, Zhang Z, Xu Z, et al. Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response. Pharmacogenomics 2013; 14:277-288
64. Ellsworth KA, Moon I, Eckloff BW, et al. FKBP5 genetic variation: Association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenet Genomics 2013; 23:156-166
65. Ganea K, Menke A, Schmidt MV, et al. Convergent animal and human evidence suggests the activin/inhibin pathway to be involved in antidepressant response. Transl Psychiatry 2012; 2:e177
66. Liou Y-J, Chen C-H, Cheng C-Y, et al. Convergent evidence from mouse and human studies suggests the involvement of zinc finger protein 326 gene in antidepressant treatment response. PLoS One 2012; 7:e32984
67. Mitjans M, Serretti A, Fabbri C, et al. Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment. Psychopharmacology 2013; 227:509-519
68. Shi Y, Yuan Y, Xu Z, et al. Genetic variation in the calcium/ calmodulindependent protein kinase (CaMK) pathway is associated with antidepressant response in females. J Affect Disord 2012; 136:558-566
69. Wang C-J, Zhang Z-J, Xu Z, et al. Kinase gene haplotypes and gene-gene interactions in the Ras-Raf-MAPK signaling pathway: Association with antidepressant remission. Int Clin Psychopharmacol 2013; 28:245-254
70. Yang Z, Ma X, Wang Y, et al. Association of APC and REEP5 gene polymorphisms with major depression disorder and treatment response to antidepressants in a Han Chinese population. Gen Hosp Psychiatry 2012; 34:571-577
71. Jaquenoud Sirot E, Harenberg S, Vandel P, et al. Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression. J Clin Psychopharmacol 2012; 32:622-629
72. Singh aB, Bousman Ca, Ng CH, et al. ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. Transl Psychiatry 2012; 2:e198
73. Musil R, Zill P, Seemüller F, et al. Genetics of emergent suicidality during antidepressive treatment: Data from a naturalistic study on a large sample of inpatients with a major depressive episode. Eur Neuropsychopharmacol 2013; 23:663-674
74. Bishop JR, Chae SS, Patel S, et al. Pharmacogenetics of glutamate system genes and SSRI-associated sexual dysfunction. Psychiatry Res 2012; 199:74-76
75. Liang C-S, Ho P-S, Chiang K-T, Su H-C. 5-HT2A receptor -1438 /A polymorphism and serotonergic antidepressant-induced sexual dysfunction in male patients with major depressive disorder: A prospective exploratory study. J Sexual Med 2012; 9:2009-2016
76. Xu Z, Zhang Z, Shi Y, et al. Influence and interaction of genetic polymorphisms in catecholamine neurotransmitter systems and early life stress on antidepressant drug response. J Affect Disord 2011; 133:165-173
77. Montminy M. Transcriptional regulation by cyclic AMP. Ann Rev Biochem 1997; 66:807-822
78. Pilar-Cué llar F, Vidal R, Díaz A, et al. Neural plasticity and proliferation in the generation of antidepressant effects: Hippocampal implication. Neural Plast 2013; 2013:537265
79. Keers R, Uher R, Huezo-Diaz P, et al. Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics J 2011; 11:138-145
80. Zill P, Büttner A, Eisenmenger W, et al. Single nucleotide polymorphism and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene in suicide victims. Biol Psychiatry 2004; 56:581-586
81. Hall-Flavin DK, Winner JG, Allen JD, et al. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry 2012; 2:e172
82. Hall-Flavin DK, Winner JG, Allen JD, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics 2013; 23:535- 548
83. Winner J, Allen JD, Altar CA, Spahic-Mihajlovic Av. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl Psychiatry 2013; 3:e242
84. Ruan?o G, Szarek BL, Villagra D, et al. Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder. Biomark Med 2013; 7:429-439
85. Breitenstein B, Scheuer S, Pfister H, et al. The clinical application of ABCB1 genotyping in antidepressant treatment: A pilot study. CNS Spectr 2013
86. Olgiati P, Bajo E, Bigelli M, et al. Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries. Prog Neuropsychopharmacol Biol Psychiatry 2012; 36:147-154